Archive · 14 Nov 2025
Indian Hospital Achieves Breakthrough in Pediatric Bone Marrow Transplants for Sickle Cell Disease
Imagine some children are born with red blood cells that are shaped like a banana instead of a donut.
This makes it hard for them to travel through the body, causing a lot of pain and problems.
Doctors at a hospital in India have found a way to fix this!
They take out the body's faulty blood-making factory (called bone marrow) and replace it with a healthy one from a donor.
This special fix is called a bone marrow transplant.
They studied over 100 children and found that many could be completely cured!
Even when they couldn't find a perfect match for the donor, they found ways to make it work.
This is great news because it means even in places where special medicine can be hard to get, children can still have a chance at a healthy life.
It’s like giving them a new start, free from the pain and sickness of sickle cell disease.
A decade-long study by Fortis Memorial Research Institute in Gurugram shows significant success in curing Sickle Cell Disease in children through bone marrow transplantation.
The study analyzed 100 paediatric cases between 2015 and 2024, achieving an overall survival rate of nearly 87%.
Success rates were high for matched sibling donor transplants (96%) and notably improved for half-matched (haploidentical) family donor transplants (78%).
These outcomes place India among leading nations in advanced paediatric transplant results, offering hope for developing countries where Sickle Cell Disease is prevalent.
The breakthrough uses advanced transplant protocols to minimize side-effects and reduce complications, making cure possible even in resource-limited settings.
- Who
- Fortis Memorial Research Institute (FMRI) in Gurugram, India, and children suffering from Sickle Cell Disease
- What
- Achieved a breakthrough in treating Sickle Cell Disease in children through bone marrow (stem cell) transplantation with high success rates.
- When
- Results published on Thursday, based on a decade-long study (2015-2024).
- Where
- Gurugram, India, with implications for developing nations worldwide, particularly India and sub-Saharan Africa.
- Why
- To offer a permanent cure for Sickle Cell Disease, which previously had limited treatment options and significantly impacts children's quality of life and life expectancy.
Advocates for advanced transplant protocols
Skeptics on accessibility in resource-limited settings
Feasibility of advanced care in developing nations
Advocates for advanced transplant protocols
The study from Fortis Memorial Research Institute demonstrates that children in developing countries like India and Africa can achieve survival rates comparable to the best global centers with timely access to advanced care, proving a cure is possible even in resource-limited settings.
Skeptics on accessibility in resource-limited settings
While the study shows promising results, the widespread accessibility and affordability of these advanced transplant protocols in resource-limited settings remain a concern, potentially limiting the impact for a larger population.
Role of haploidentical transplants
Advocates for advanced transplant protocols
Significant progress has been made in haploidentical (half-matched) transplants using parental donors, with reduced-toxicity conditioning and post-transplant cyclophosphamide protocols lowering complication rates, making the treatment safer and more widely applicable.
Skeptics on accessibility in resource-limited settings
While haploidentical transplants offer an alternative when a full sibling match is unavailable, the success rates, though improved, are still lower than matched sibling donor transplants, and the complexity of these procedures may still pose challenges in certain settings.
- Institution
- Fortis Memorial Research Institute (FMRI), Gurugram
- Study Focus
- Bone marrow (stem cell) transplantation for Sickle Cell Disease in children
- Study Period
- 2015-2024
- Number of Cases
- 100 paediatric cases
- Overall Survival Rate
- Nearly 87%
- Success Rate (Matched Sibling Donor)
- 96%
- Success Rate (Half-Matched/Haploidentical Donor)
- 78%
- Published In
- International journal ‘Haemoglobin’